AUS
NZ
UK
CA
USA
IND
Healthcare
Novo Nordisk Outpaces Expectations with Wegovy Sales Surge, Raises Outlook Amid Pricing Pressures
November 06, 2024 09:25 PM GMT| By Team Kalkine MediaHighlights:,Wegovy Sales Surge Past Forecasts:,Sales of Novo Nordisk's weight-loss drug, Wegovy, soared to $2.49 billion, surpassing analyst projections and signaling strong market demand.,Robust Group Sales Growth:,Despite a slight miss in total sal...
Spire Healthcare Advances with Strategic Share Buyback
November 06, 2024 08:21 AM GMT| By Team Kalkine MediaHighlights:,Spire Healthcare Group executes a share repurchase, acquiring 50,000 ordinary shares.,The repurchase reduces the total number of shares in circulation to 403,988,352.,This move reflects Spire's financial strength and aims to enhance share...
Poolbeg Pharma’s POLB 001 Shows Promise in Reducing CRS Severity in Cancer Immunotherapy
November 06, 2024 07:58 AM GMT| By Team Kalkine MediaHighlights:,Preventative Potential,:,POLB 001,demonstrated,success in reducing cytokine release syndrome (CRS) severity in preclinical models.,Clinical Accessibility,:,The drug could broaden access to cancer immunotherapies, making outpatient treatme...
Roquefort Therapeutics Advances STAT-6 siRNA Research in Immunology and Oncology
November 06, 2024 07:40 AM GMT| By Team Kalkine MediaHighlights:,Innovative Gene-Targeting Approach,:,Roquefort’s STAT-6 siRNA,programme,targets inflammation and immune response at the genetic level.,Promising Reductions in Inflammatory Markers,:,Data show a tenfold decrease in STAT-6 protein and reduc...
AstraZeneca Loses £15bn in Value Over Weight Loss Drug Data, China Fraud News
November 05, 2024 04:47 PM GMT| By Team Kalkine MediaHighlights:,Early Data Disappoints on Weight Loss Drug:,AstraZeneca presented preliminary data for its GLP-1 weight loss drug, which fell short of some analysts’ expectations.,China Investigation Impact:,Reports indicate several AstraZeneca China exe...
hVIVO PLC to Showcase Insights at Jefferies London Healthcare Conference
November 05, 2024 08:31 AM GMT| By Team Kalkine MediaHighlights:,hVIVO CEO, Yamin 'Mo' Khan, will present at the Jefferies Healthcare Conference in London on 19 November 2024 at 12:00pm GMT.,The Jefferies Healthcare Conference is the largest of its kind in Europe, attracting over 650 healthcare compani...
International Biotechnology Trust Reports Strong NAV Growth and Strategic Success
November 05, 2024 07:59 AM GMT| By Team Kalkine MediaHighlights,Strong NAV Performance,: NAV rose 15.9%, outperforming the NASDAQ Biotechnology Reference Index’s 15.3% gain.,Strategic Investment Gains,: Success in M&A and unquoted investments contributed significantly to the Trust's outperformance.,Gov...
Spire Healthcare’s Buyback of Shares Successfully Completed
November 05, 2024 07:42 AM GMT| By Team Kalkine MediaHighlights:,Spire Healthcare has repurchased 50,000 of its ordinary shares on the London Stock Exchange.,The share repurchase forms part of the company's ongoing buyback program.,Following the transaction, Spire Healthcare’s total number of shares in...
Ondine Biomedical Launches £8.5 Million Fundraising Effort for U.S. Phase 3 Clinical Trial
November 01, 2024 07:22 AM GMT| By Team Kalkine MediaHighlights,Fundraising targets at least £8.5 million to fund a U.S. Phase 3 clinical trial for Ondine’s nasal photodisinfection technology.,A 36% increase in issued share capital is anticipated, with New Common Shares priced at 8.5 pence each.,Additi...
Smith+Nephew Q3 2024 Trading Update: Revenue Growth Moderates Amid China Headwinds, Positive 2025 Outlook
October 31, 2024 05:58 PM GMT| By Team Kalkine MediaHighlights,Q3 revenue rose 4% YoY to $1,412 million, with strong growth outside China.,Orthopaedics, Sports Medicine, and Advanced Wound Management segments all showed gains.,2024 full-year revenue growth outlook revised to 4.5% due to China headwind...
Avacta Therapeutics Showcases Next Generation of pre|CISION® Medicines at R&D Spotlight Event
October 30, 2024 10:26 AM GMT| By Team Kalkine MediaHighlights,Avacta Therapeutics hosted a live R&D Spotlight event in London, focusing on its next-generation peptide drug conjugates (PDC) aimed at targeted tumor treatment.,The company presented details about its innovative pre|CISION® candidates and...
GSK Adjusts Vaccine Sales Forecast as Q3 Holds Steady, Analysts See Potential
October 30, 2024 10:23 AM GMT| By Team Kalkine MediaHighlights:,Vaccine Sales Fall Short:,Arexvy and Shingrix sales missed forecasts, leading to a second downgrade in GSK’s vaccine segment.,Overall Growth Maintained:,Revenues rose by 2% to £8 billion, with core EPS up 5% at 49.7p, driven by specialty...
GSK Maintains Positive Trajectory for 2024 Amid R&D Advances
October 30, 2024 10:12 AM GMT| By Team Kalkine MediaHighlights,GSK's Q3 2024 sales reached £8.0 billion, reflecting a 2% decline at actual exchange rates (AER) but a 2% increase at constant exchange rates (CER).,Specialty Medicines showed robust growth, with sales up 19%, counterbalancing a significan...
Eli Lilly Shares Fall as Company Lowers Year-End Guidance After Q3 Revenue Miss
October 30, 2024 10:00 AM GMT| By Team Kalkine MediaHighlights:,Lowered Annual Guidance:,Eli Lilly reduced its earnings forecast to $13.02–$13.52 per share, down from $16.10–$16.60.,Zepbound,Sales Miss Estimates:,Q3 sales of weight-loss drug,Zepbound,came in at,$1.26 billion,, falling short of the pro...
A decline in full year 2024 earnings is noted by Bioventix
October 30, 2024 09:45 AM GMT| By Team Kalkine MediaHighlights,Bioventix reported a 6.2% increase in revenue for FY 2024, totaling £13.6 million, despite missing analyst estimates.,Net income decreased by 3.3%, resulting in an earnings per share (EPS) of £1.55, down from £1.61 in FY 2023.,The company’...
GSK sees a rise in quarterly sales, and Next enhances its full-year guidance
October 30, 2024 08:45 AM GMT| By Team Kalkine MediaHighlights,GSK reported a 2% increase in constant exchange rate sales to £8 billion, driven by growth in specialty medicines despite a decline in vaccine sales.,Next raised its guidance for both fourth-quarter and full-year performance following a 7....
Hemogenyx Pharmaceuticals PLC outlines the schedule for its Phase I clinical trial
October 30, 2024 07:53 AM GMT| By Team Kalkine MediaHighlights,Hemogenyx Pharmaceuticals plc has announced the schedule for launching its Phase I clinical trial for HEMO-CAR-T (HG-CT-1), targeting relapsed/refractory acute myeloid leukemia (AML) in adults.,Institutional Review Board (IRB) approval for...
Strong Q3 Results Boost Shield Therapeutics’ Financial Health Ahead of 2025
October 29, 2024 11:39 AM GMT| By Team Kalkine MediaHighlights:,Shield Therapeutics (LSE:STX) reports robust Q3 revenue, driven by increased demand for Accrufer.,The company secures additional financing and targets positive cash flow by the end of 2025.,A potential $10 million equity investment from A...
Olympus Hit by Leadership Crisis as CEO Steps Down Amid Drug Scandal
October 28, 2024 08:21 AM GMT| By Team Kalkine MediaHighlights:,Olympus CEO Stefan Kaufmann resigned after an internal probe into allegations of illegal drug purchases.,Kaufmann, the second non-Japanese CEO of the company, served since April 2023.,Chairman Yasuo Takeuchi will act as interim CEO while...
Three UK Stocks Highlighted for Possible Undervaluation of Up to 40.3%
October 24, 2024 09:57 AM BST| By Team Kalkine MediaHighlights,Market Downturn,: The UK stock market, including the FTSE 100 and FTSE 250, has faced recent declines influenced by weak trade data from China, affecting companies reliant on its economy.,Identifying Opportunities,: Amidst market challenge...
